Kurt von Emster, Interim Chairman
Managing Partner – Abingworth LLP
Mr. von Emster joined Abingworth in January 2015 and now serves as its Managing Partner, bringing over 25 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies CRISPR Therapeutics, Kesios Therapeutics and SutroVax. In addition, he is on the boards of CymaBay. Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics and is a CFA. He is based in Menlo Park.